Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
Saved in:
| Title: | Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. |
|---|---|
| Authors: | Byngsu Kim, Eui Yul Choi, Chang Yoon Kim, Kyuyung Song, Yeon Ho Joo |
| Source: | Human Psychopharmacology: Clinical & Experimental. Jan2008, Vol. 23 Issue 1, p61-67. 7p. 3 Charts. |
| Subjects: | Serotonin, Cell receptors, Dopamine receptors, Risperidone, Schizophrenia treatment |
| Abstract: | Objective This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting. Methods We consecutively recruited 100 schizophrenia patients and assessed clinical improvement after 4 weeks of risperidone treatment. Results The patients with T/T in the HTR2A gene showed less clinical improvement than did those with T/C or C/C (p = 0.044). In the case of the DRD3 gene, we did not find statically significant association with clinical improvement (p = 0.061). When patients were categorized into responders and nonresponders, the C allele was more frequent in responders (OR = 2.28, 95%CI = 1.06–4.91, p = 0.039). When combinations of the two polymorphisms were considered, patients who had T/T in the HTR2A gene and encoded Ser/Ser or Ser/Gly from DRD3 gene had a higher propensity to non-responsiveness compared to other subjects (OR = 3.57, 95%CI = 1.10–11.62, p = 0.039). Conclusions Our findings suggest that the HTR2A T102C could be a potential indicator of clinical improvement after risperidone treatment. Copyright © 2007 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR] |
| Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 28548946 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Byngsu+Kim%22">Byngsu Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Eui+Yul+Choi%22">Eui Yul Choi</searchLink><br /><searchLink fieldCode="AR" term="%22Chang+Yoon+Kim%22">Chang Yoon Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Kyuyung+Song%22">Kyuyung Song</searchLink><br /><searchLink fieldCode="AR" term="%22Yeon+Ho+Joo%22">Yeon Ho Joo</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Human+Psychopharmacology%3A+Clinical+%26+Experimental%22">Human Psychopharmacology: Clinical & Experimental</searchLink>. Jan2008, Vol. 23 Issue 1, p61-67. 7p. 3 Charts. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Serotonin%22">Serotonin</searchLink><br /><searchLink fieldCode="DE" term="%22Cell+receptors%22">Cell receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Dopamine+receptors%22">Dopamine receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Risperidone%22">Risperidone</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia+treatment%22">Schizophrenia treatment</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Objective This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of these alleles predicts clinical improvement in a naturalistic setting. Methods We consecutively recruited 100 schizophrenia patients and assessed clinical improvement after 4 weeks of risperidone treatment. Results The patients with T/T in the HTR2A gene showed less clinical improvement than did those with T/C or C/C (p = 0.044). In the case of the DRD3 gene, we did not find statically significant association with clinical improvement (p = 0.061). When patients were categorized into responders and nonresponders, the C allele was more frequent in responders (OR = 2.28, 95%CI = 1.06–4.91, p = 0.039). When combinations of the two polymorphisms were considered, patients who had T/T in the HTR2A gene and encoded Ser/Ser or Ser/Gly from DRD3 gene had a higher propensity to non-responsiveness compared to other subjects (OR = 3.57, 95%CI = 1.10–11.62, p = 0.039). Conclusions Our findings suggest that the HTR2A T102C could be a potential indicator of clinical improvement after risperidone treatment. Copyright © 2007 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=28548946 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/hup.897 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 7 StartPage: 61 Subjects: – SubjectFull: Serotonin Type: general – SubjectFull: Cell receptors Type: general – SubjectFull: Dopamine receptors Type: general – SubjectFull: Risperidone Type: general – SubjectFull: Schizophrenia treatment Type: general Titles: – TitleFull: Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Byngsu Kim – PersonEntity: Name: NameFull: Eui Yul Choi – PersonEntity: Name: NameFull: Chang Yoon Kim – PersonEntity: Name: NameFull: Kyuyung Song – PersonEntity: Name: NameFull: Yeon Ho Joo IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: Jan2008 Type: published Y: 2008 Identifiers: – Type: issn-print Value: 08856222 Numbering: – Type: volume Value: 23 – Type: issue Value: 1 Titles: – TitleFull: Human Psychopharmacology: Clinical & Experimental Type: main |
| ResultId | 1 |
